Clinical efficacy of sulbactam-durlobactam in treating patients with carbapenem-resistant Acinetobacter baumannii pulmonary infection and drug concentration surveillance
10.11816/cn.ni.2025-251384
- VernacularTitle:舒巴坦度洛巴坦治疗耐碳青霉烯类鲍曼不动杆菌肺部感染的临床效果及药物浓度监测
- Author:
Yue CHEN
1
;
Lin QIAO
1
;
Zhongyao XIE
1
;
Wenqian CHEN
1
;
Dongjie GUO
1
;
Pengmei LI
1
Author Information
1. 中日友好医院药学部,北京 100029
- Publication Type:Journal Article
- Keywords:
Carbapenem-resistant Acinetobacter baumannii;
Pulmonary infection;
Sulbactam;
Sulbactam-durlobactam;
Therapeutic drug monitoring
- From:
Chinese Journal of Nosocomiology
2025;35(20):3105-3109
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy of sulbactam-durlobactam combined with meropenem in treating carbapenem-resistant Acinetobacter baumannii(CRAB)pulmonary infection.METHODS A total of 16 patients treated at China-Japan Friendship Hospital from Jan.1,2025 to Jun.1,2025 were included.Retrospective analy-sis was conducted on patients'basic situation,preliminary treatment regimens,infection-related diagnoses,etiolo-gy and clinical outcomes.Therapeutic drug monitoring(TDM)for sulbactam was also performed.RESULTS By the end of the treatment course,13 patients achieved etiological eradication of CRAB and clinical improvement,while 1 patient experienced CRAB recurrence within one month.Three patients showed treatment failure.TDM for sulbactam was performed in 13 patients.Except for one slightly lower,all achieved trough plasma concentra-tions above the minimum inhibitory concentration(MIC)(100％T＞MIC,MIC=4 mg/L based on clinical breakpoints).Dosage adjustments based on plasma concentrations were made for 4 patients,with 3 receiving re-duced doses and 1 receiving an increased dose.CONCLUSIONS Sulbactam-durlobactam combined with meropenem demonstrates superior efficacy in treating CRAB compared to other regimens.Under the recommended dosage,all patients can achieve the PK/PD target for sulbactam.
